



SDI Review Form 1.6

Journal Name:	Journal of Advances in Medical and Pharmaceutical Sciences
Manuscript Number:	Ms_JAMPS_49029
Title of the Manuscript:	USE OF MICA FUNGIN FOR THE MANAGEMENT OF A CLUSTER OF INVASIVE ASPERGILLOSIS IN CHILDREN WITH CANCER
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	This is well written paper, describing the role of micafungin in neutropenic patients after chemotherapy. In this monoinstitutional report no evidence of breakthrough infections were detected despite 4 positive GMs.	
Minor REVISION comments	Have the authors experience on IFI prophylaxis and breakthrough infections with other drugs in their center? Can they compare prophylactic strategies in children in a table? This could help readers throughout the paper.	
Optional/General comments	Introduction and discussion are too long	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

Reviewer Details:

Name:	Massimo Berger
Department, University & Country	University of Turin , Italy